| Literature DB >> 23064078 |
Yuki Shiotsuka1, Miki Uebuchi, Seiji Hamada, Naofumi Morita, Akira Moriyama, Mayuko Yamashita, Yasuko Ichikawa, Hiroshi Fujii, Akinobu Matsuo, Hiroshi Kuhara, Yoshiaki Ikuta, Satoshi Ikeshima, Masafumi Kuramoto, Kenichiro Fujii, Shinya Shimada.
Abstract
Seven patients who had been receiving capecitabine+oxaliplatin±bevacizumab(CapeOX±BV)therapy at our hospital between February 2010 and March 2011, had complained of angialgia during oxaliplatin(L-OHP)administration. Therefore, 3. 3 mg of dexamethasone(DEX)was added to their infusion solution. The patients were then asked to rate their angialgia severity using a numerical rating scale(NRS), when L-OHP in a 5% dextrose solution was administered with or without DEX. By changing the L-OHP in 5% dextrose solution without DEX to the solution containing 3. 3 mg of DEX, the mean NRS was improved to 2. 4 from 7. 1. These findings indicate that L-OHP in 5% dextrose solution mixed with 3. 3 mg of DEX seems to be useful in reducing angialgia during peripheral administration of L-OHP.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23064078
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN: 0385-0684